Gossamer Bio Inc. has released its financial results for the second quarter ended June 30, 2025. The company reported a net loss of $38.3 million, contrasting with a net income of $49.2 million for the same period in 2024. This change is primarily due to the absence of $88.8 million in one-time license revenue recognized in the second quarter of 2024 from a collaboration with Chiesi. For the quarter ended June 30, 2025, the company generated $11.5 million in revenue associated with the Chiesi collaboration, a significant decline from the $95.8 million reported in the same quarter of the previous year. Research and Development expenses increased to $41.6 million from $35.1 million in 2024, while General and Administrative expenses remained steady at $8.7 million. Gossamer Bio reported cash, cash equivalents, and marketable securities totaling $213 million as of June 30, 2025. The company anticipates that this financial position will fund its operating and capital expenditures into 2027. In terms of business operations, Gossamer Bio is advancing with commercial planning for seralutinib in partnership with Chiesi Group, as it transitions from a clinical-stage biotech to a commercial organization. The company is also preparing to initiate a global, registrational Phase 3 study in pulmonary hypertension associated with interstitial lung disease (PH-ILD), with the first clinical sites expected to be activated in the fourth quarter of 2025.